A non-hallucinogenic psychedelic analogue with therapeutic potential.
Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, Vargas MV, McCarroll MN, Taylor JC, Myers-Turnbull D, Liu T, Yaghoobi B, Laskowski LJ, Anderson EI, Zhang G, Viswanathan J, Brown BM, Tjia M, Dunlap LE, Rabow ZT, Fiehn O, Wulff H, McCorvy JD, Lein PJ, Kokel D, Ron D, Peters J, Zuo Y, Olson DE.
Nature. 2021 Jan;589(7842):474-479. doi: 10.1038/s41586-020-3008-z. Epub 2020 Dec 9.
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE.
Neuropharmacology. 2018 Nov;142:143-166. doi: 10.1016/j.neuropharm.2018.05.012. Epub 2018 Jun 5.
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L.
JAMA Psychiatry. 2022 Oct 1;79(10):953-962. doi: 10.1001/jamapsychiatry.2022.2096.
Therapeutic effect of psilocybin in addiction: A systematic review.
van der Meer PB, Fuentes JJ, Kaptein AA, Schoones JW, de Waal MM, Goudriaan AE, Kramers K, Schellekens A, Somers M, Bossong MG, Batalla A.
Front Psychiatry. 2023 Feb 9;14:1134454. doi: 10.3389/fpsyt.2023.1134454. eCollection 2023.
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.
Noller GE, Frampton CM, Yazar-Klosinski B.
Am J Drug Alcohol Abuse. 2018;44(1):37-46. doi: 10.1080/00952990.2017.1310218. Epub 2017 Apr 12.
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR.
J Psychopharmacol. 2014 Nov;28(11):983-92. doi: 10.1177/0269881114548296. Epub 2014 Sep 11.
Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: Review of modalities and implications for treatment.
Mahoney JJ 3rd, Hanlon CA, Marshalek PJ, Rezai AR, Krinke L.
J Neurol Sci. 2020 Nov 15;418:117149. doi: 10.1016/j.jns.2020.117149. Epub 2020 Sep 20.
Hallucinogens: an update.
Halpern JH.
Curr Psychiatry Rep. 2003 Oct;5(5):347-54. doi: 10.1007/s11920-003-0067-4.
Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview.
Ona G, Reverte I, Rossi GN, Dos Santos RG, Hallak JE, Colomina MT, Bouso JC.
J Psychopharmacol. 2023 Dec;37(12):1190-1200. doi: 10.1177/02698811231200882. Epub 2023 Nov 8.
Treating posttraumatic stress disorder and alcohol use disorder comorbidity: Current pharmacological therapies and the future of MDMA-integrated psychotherapy.
Gully BJ, Eaton E, Capone C, Haass-Koffler CL.
J Psychopharmacol. 2023 Dec;37(12):1182-1189. doi: 10.1177/02698811231200880. Epub 2023 Nov 27.
